Evidence that fluoride therapy increases trabecular bone density in a peripheral skeletal site

Area of Science:

• Bone Metabolism and Osteoporosis Research
• Pharmacological Interventions for Bone Health

Background:

• Osteoporosis is characterized by reduced bone density, increasing fracture risk.
• Untreated osteoporotic females exhibit significantly lower spinal bone density (SBD) and femoral condyle bone density (FCD) compared to controls.
• Bone density measurements are crucial for assessing osteoporosis severity and treatment efficacy.

Purpose of the Study:

• To evaluate the effect of fluoride therapy on SBD and FCD in osteoporotic females.
• To determine if fluoride's osteogenic action extends beyond the axial skeleton.
• To assess the correlation between SBD and FCD before and during fluoride treatment.

Main Methods:

• Bone density was measured in 219 normal and osteoporotic females before and during fluoride therapy.
• Statistical analyses, including correlation (r) and significance (P) values, were employed.
• Average rates of bone density increase were calculated in mg/cc/month.

Main Results:

• Significant correlations were observed between SBD and FCD in both untreated (r = 0.62) and fluoride-treated (r = 0.42) osteoporotic groups.
• Fluoride therapy led to significant increases in both SBD and FCD (P < 0.05).
• The average rates of increase in FCD and SBD were comparable, suggesting a similar response to fluoride therapy.

Conclusions:

• Fluoride therapy demonstrates osteogenic action not confined to the axial skeleton.
• An increase in trabecular bone density occurs at peripheral weight-bearing sites, such as the femoral condyle.
• Fluoride is a potential therapeutic agent for improving bone density in osteoporosis at both central and peripheral sites.